Penn Vet | Cancer Clinical Trial - HEMANGIOSARCOMA - Supplement for Dogs with Cancer of the Spleen
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
Ryan Hospital Philadelphia, PA

HEMANGIOSARCOMA - Supplement for Dogs with Cancer of the Spleen

Dec 6, 2013

In a previous study conducted here at PennVet, the mushroom supplement I’m-Yunity® significantly increased survival time in dogs with splenic hemangiosarcoma. I’m-Yunity® extract effectively delivers the standardized ingredient polysaccharopeptide (PSP) which can only be isolated from the Coriolus Versicolor mushroom. 

In this new trial, we will be comparing I’m-Yunity’s® effect on survival time and quality of life to the standard chemotherapy treatment.

Dogs in this study will be treated with standard of care chemotherapy (doxorubicin). Half of the dogs will be randomly chosen to receive I'm Yunity® concurrently with the chemotherapy, and owners will not know whether or not their dog is getting I'm Yunity®.  Dogs enrolled in this study will have 11 weekly visits, followed by monthly follow-up visits until the end of their life.


  • Diagnosis of hemangiosarcoma following splenectomy.
  • At least 4 kg.
  • Not currently undergoing treatment for cancer.
  • No other significant health concerns that are an immediate threat to life.
  • Ability to administer oral medication (pills) to your dog.
Please contact the VCIC at 215-573-0302 or for more information about this study.